News | February 02, 2022
Panacea Biotec sells its domestic formulations business to Mankind Pharma
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The country is sixth among the most affected countries by active cases
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Ram’s appointment follows the launch of the CDI India division in October 2021.
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Subscribe To Our Newsletter & Stay Updated
